EVALUATION OF BISPECTRAL INDEX MONITORING IN GENERAL ANAESTHESIA THROUGH A HEALTH TECHNOLOGY ASSESSMENT METHOD: A POSSIBLE INTRODUCTION IN CLINICAL PRACTICE IN AN ITALIAN HOSPITAL? (submitted in 2019)
1ISG-014
COST EFFECTIVENESS ANALYSIS OF PATIENTS' SELF-ADMINISTRATION OF MEDICATION (SAM) DURING HOSPITALISATION IN A CARDIOLOGY UNIT (submitted in 2019)
1ISG-013
SMARTPHONE APPLICATIONS FOR PATIENTS DIAGNOSED WITH GENITOURINARY TUMOURS: ANALYSIS OF THE QUALITY USING THE MOBILE APPLICATION RATING SCALE (submitted in 2019)
1ISG-012
NATIONAL REPORTING SYSTEM FOR DRUG SHORTAGES : CLASSIFICATION AND TRENDS IN REPORTED CAUSES FROM 2015 TO 2018 (submitted in 2019)
1ISG-011
ASSESSMENT OF ASTHMA DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY AND RELATED COST IN THE VENETO REGION (submitted in 2019)
1ISG-010
INTRODUCTION OF RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO IMPROVE HEALTH SYSTEM EFFICIENCY? (submitted in 2019)
1ISG-009
BUDGET IMPACT ANALYSIS OF A NATALIZUMAB EXTENDED INTERVAL DOSING REGIMEN (submitted in 2019)
1ISG-008
COST EFFICACY ANALYSIS OF ABIRATERONE IN NEWLY DIAGNOSED HIGH RISK METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (submitted in 2019)
1ISG-007
NEW CANCER DRUGS APPROVALS IN PORTUGAL (submitted in 2019)
1ISG-006
EFFECTIVENESS EVALUATION OF HIGHCOST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION (submitted in 2019)
1ISG-005
ABC-VEN CROSSTAB ANALYSIS: A DECISION MAKING SYSTEM APPLIED FOR ANTICANCER MEDICINES (submitted in 2019)
1ISG-004
ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE OF TREATMENT MULTIPLE MYELOMA (submitted in 2019)
1ISG-003
STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE (submitted in 2019)
1ISG-002
BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS (submitted in 2019)
1ISG-001
CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE? (submitted in 2019)
